Johnson & Johnson’s three-year TREMFYA data highlight why sustained remission is redefining ulcerative colitis treatment decisions. Read the analysis.
Early YOLT-202 data from YolTech Therapeutics suggests gene editing could redefine Alpha-1 Antitrypsin Deficiency treatment. Read the analysis.
Enveric Biosciences reports new EB-003 signaling data. Find out what this means for non-hallucinogenic antidepressant development and regulatory risk.
Pilatus Biosciences earns FDA Fast Track for PLT012 in liver cancer. Read why CD36 targeting could reshape immunotherapy development.
GE HealthCare’s FDA-cleared SIGNA MRI systems signal a shift toward autonomous, helium-free imaging. Explore what this means for MRI operations.
ImmunityBio expands ANKTIVA into Europe with Accord Healthcare. Discover what this means for bladder cancer care, regulation, and real-world adoption.
Belay Diagnostics validates its Summit 2.0 CSF genomic assay, strengthening the clinical case for liquid biopsy in CNS cancers. Read the full analysis.
Sibel Health secures FDA acceptance for its Aria cough sensor. Find out what this could change for chronic cough drug trials and digital endpoints.
NCCN guidelines now recommend Merlin CP-GEP for early-stage melanoma risk assessment. Discover what this changes for clinicians and diagnostics adoption.
Bimini Health Tech secures FDA clearance for Puregraft SYNC. Explore what it changes for fat grafting workflows, adoption economics, and device strategy.